CATX Perspective Therapeutics, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 728387 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-16.2%
TTM EPS YoY16.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-45.8%
ROA-37.2%
ROIC (approx.)-44.1%
Asset turnover—
Leverage & solvency
Liabilities / assets19.4%
Debt / equity0.01x
Current ratio5.18x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.88x
Accruals ratio-4.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $26.07M | $21.54M | $21.37M | $32.92M | $20.34M | $16.62M | $14.33M | $12.88M |
| SG&A expense | $8.27M | $7.79M | $6.99M | $6.95M | $7.73M | $7.71M | $7.84M | $8.25M |
| Operating income | -$34.32M | -$29.26M | -$28.28M | -$39.83M | -$27.86M | -$24.04M | -$21.83M | -$44.98M |
| Pretax income | -$32.44M | -$26.98M | — | -$38.28M | -$25.97M | -$22.00M | -$18.18M | -$42.27M |
| Net income | -$32.44M | -$26.79M | -$26.19M | -$37.49M | -$25.97M | -$21.48M | -$18.18M | -$40.17M |
| EBITDA | -$33.13M | -$28.12M | -$27.16M | -$38.82M | -$27.09M | -$23.31M | -$21.10M | -$44.26M |
| EPS (basic) | -0.27 | -0.22 | -0.25 | — | -0.35 | -0.29 | -0.25 | — |
| EPS (diluted) | -0.27 | -0.22 | -0.25 | — | -0.35 | -0.29 | -0.25 | — |
| Weighted avg. shares (diluted) | 120.75M | 120.65M | 103.60M | — | 74.30M | 74.23M | 72.36M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $41.04M | $48.49M | $53.97M | $30.63M | $26.76M | $28.85M | $44.41M | $61.58M |
| Short-term investments | $160.65M | $188.39M | $216.96M | $114.11M | $147.38M | $162.73M | $167.30M | $165.34M |
| Receivables | $13,000 | $269,000 | $58,000 | $6,000 | $179,000 | $225,000 | $78,000 | $116,000 |
| Current assets | $205.28M | $241.52M | $275.35M | $148.39M | $178.50M | $195.96M | $215.74M | $231.16M |
| PP&E, net | $117.92M | $107.80M | $92.48M | $76.60M | $64.35M | $62.60M | $61.25M | $57.32M |
| Goodwill | — | — | — | — | — | — | — | $0 |
| Intangibles | — | — | — | $362,000 | — | — | — | $279,000 |
| Total assets | $365.68M | $392.02M | $410.77M | $266.97M | $294.82M | $310.73M | $329.35M | $341.10M |
| Current liabilities | $39.60M | $36.54M | $31.49M | $28.68M | $20.62M | $12.99M | $12.68M | $18.23M |
| Long-term debt | $1.58M | $1.60M | $1.61M | $1.62M | $1.64M | $1.65M | $1.66M | $1.68M |
| Total debt | $1.58M | $1.60M | $1.61M | $1.62M | $1.64M | $1.65M | $1.66M | $1.68M |
| Total liabilities | $71.00M | $68.16M | $63.33M | $59.94M | $52.61M | $45.03M | $44.70M | $50.43M |
| Shareholders' equity | $294.68M | $323.86M | $347.44M | $207.03M | $242.22M | $265.69M | $284.64M | $290.67M |
| Net debt | -$39.46M | -$46.89M | -$52.36M | -$29.00M | -$25.12M | -$27.20M | -$42.74M | -$59.90M |
| Shares outstanding | 114.16M | 114.09M | 114.02M | 74.34M | 74.34M | 74.26M | 74.05M | 70.67M |
| Cash flow statement | ||||||||
| Operating cash flow | -$31.35M | -$20.65M | -$31.47M | -$24.66M | -$16.29M | -$19.95M | -$21.58M | -$26.61M |
| Capital expenditure | $4.54M | $14.20M | $6.86M | $5.08M | $1.99M | $1.03M | $4.66M | $14.61M |
| Free cash flow | -$35.89M | -$34.84M | -$38.33M | -$29.73M | -$18.28M | -$20.98M | -$26.24M | -$41.22M |
| Investing cash flow | $23.73M | $15.02M | -$109.55M | $28.54M | $13.99M | $4.26M | -$5.57M | -$138.60M |
| Financing cash flow | $175,000 | $147,000 | $164.36M | -$13,000 | $213,000 | $132,000 | $9.97M | $345,000 |
| Depreciation & amortization | $1.19M | $1.14M | $1.13M | $1.01M | $775,000 | $733,000 | $732,000 | $721,000 |
| Stock-based compensation | $3.13M | $3.05M | $2.55M | $2.31M | $2.16M | $2.40M | $2.10M | $2.06M |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.